Henry B. Koon, MD is a physician scientist who has over 20 years of experience in Medical Oncology and Drug development. He joins Elevation Oncology from BioNTech where he was a Senior Director in Clinical Development who partnered with the business development group to evaluate potential collaboration assets. Prior to joining BioNTech, he was the Clinical Development Lead for the anti-CTLA4 Probody and bempegaldesleukin programs at Bristol Myers Squibb. As the Clinical Development Lead, he oversaw clinical studies in melanoma as well as gastrointestinal, genitourinary and breast cancers. He initially joined BMS as a Clinical Trial Physician for melanoma and bladder cancer studies in the nivolumab and Indoleamine 2,3-dioxygenase (IDO) inhibitor programs.
Before transitioning to industry, Henry was an Associate Professor at the Case Western Reserve School of Medicine / Case Comprehensive Cancer Center (CCC) focused on cutaneous malignancies and sarcoma. He served as Chair and Co-chair of Case Comprehensive Cancer Center Protocol Review and Monitoring Committee and a member of the Institutional Review Board. He was the Medical Oncology Lead for the Cutaneous Malignancy Program and Sarcoma Programs at the Seidman Cancer Center / University Hospitals.
He completed his Hematology / Oncology fellowship at Beth Israel Deaconess Medical Center (BIDMC). After his fellowship, he participated in the AIDS Malignancy Clinician Scientist Training program. During his faculty appointment at BIDMC he conducted translational research in AIDS malignancy investigating the use of signal transduction inhibitors and angiogenesis inhibitors in the treatment of Kaposi’s sarcoma. In addition, as a member of the Biologics/Cutaneous Malignancy Group at BIDMC, he was a clinical investigator focused on the use of immunotherapy in GU cancer and melanoma.